SVP at Century Therapeutics (IPSC) sells shares to cover taxes

Rhea-AI Filing Summary

Century Therapeutics, Inc. Senior Vice President of Finance & Operations Douglas Carr completed an automatic sale of 264 shares of common stock at $2.341 per share. The sale was made solely to cover tax withholding obligations arising from the vesting of restricted stock units and was not at his discretion.

Following this tax-related sale, Carr directly holds 506,997 shares of Century Therapeutics common stock, indicating that the transaction represents a very small portion of his overall equity position.

Insider Trade Summary

Net Seller: 264 shares ($618)

Net Sell 1 txn

Insider Carr Douglas

Role SVP Finance & Operations

Sold 264 shs ($618.02)

Type	Security	Shares	Price	Value
Sale	Common Stock	264	$2.341	$618.02

Holdings After Transaction: Common Stock — 506,997 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 264 shares Sale price: $2.341 per share Shares held after: 506,997 shares +1 more

4 metrics

Shares sold 264 shares Common stock sold to cover tax withholding

Sale price $2.341 per share Price for Century Therapeutics common stock in this transaction

Shares held after 506,997 shares Direct holdings of Douglas Carr after transaction

Net buy/sell shares -264 shares Net effect of reported transactions, indicating a small net sale

Key Terms

restricted stock units, tax withholding obligations, open-market sale

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"to cover tax withholding obligations in connection with the vesting"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carr Douglas

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 11TH FLOOR

(Street)

PHILADELPHIA PENNSYLVANIA 19104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP Finance & Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		S(1)		264	D	$2.341	506,997	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

	/s/ Douglas Carr	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Century Therapeutics (IPSC) report for Douglas Carr?

Douglas Carr, SVP Finance & Operations at Century Therapeutics, sold 264 common shares at $2.341 each. The sale was automatic and executed solely to satisfy tax withholding obligations tied to restricted stock unit vesting, rather than a discretionary portfolio decision.

Why did Century Therapeutics (IPSC) executive Douglas Carr sell 264 shares?

The 264 shares were sold to cover tax withholding obligations from vesting restricted stock units. According to the footnote, these sales were automatic and not at Douglas Carr’s discretion, meaning they were driven by tax requirements rather than active trading choices.

How many Century Therapeutics (IPSC) shares does Douglas Carr hold after the sale?

After the tax-related sale, Douglas Carr directly holds 506,997 shares of Century Therapeutics common stock. This shows the 264 shares sold represent only a very small fraction of his total holdings, suggesting the transaction is minor in proportional terms.

Was the Century Therapeutics (IPSC) insider sale an open-market trade signal?

Although coded as a sale, the transaction was executed to cover tax withholding on restricted stock unit vesting. The footnote states the sales were automatic and not at Douglas Carr’s discretion, so they do not reflect an active open-market trading decision.

What price did Douglas Carr receive for the Century Therapeutics (IPSC) shares sold?

The 264 Century Therapeutics common shares were sold at an average price of $2.341 per share. This price applies only to this small tax-related transaction and does not, by itself, indicate broader valuation judgments by the executive.